Table 4. CEC follow up in patients with SC treprostinil therapy.
| Patient | CEC per mL at Baseline before adding SC- treprostinil | Treatment at baseline before adding SC- treprostinil | CEC per mL at H48 after adding SC-treprostinil | CEC per mL at Day 5 after adding SC- treprostinil | CEC per mL at 1 month after adding SC-treprostinil | Worsening after more than 1 month of SC-treprostinil 0 = no 1 = yes | CEC per mL at pre-worsening | CEC per mL at worsening (Months after pre-worsening) | clinical event at worsening | CEC per mL post worsening | action after worsening |
| 1 | 6 | oral bitherapy | 5 | 0 | 0 | 0 | / | / | / | / | / |
| 2 | 79 | oral bitherapy | 0 | 0 | 2 | 1 | 0 | 79 (6 months) | NYHA IV | 2 | increasing doses of treprostinil |
| 3 | 44 | oral bitherapy | 0 | 0 | 1 | 1 | 39 | 251 (6 months) | cyanosis, dyspnea | 11 | epoprostenol IV |
| 4† | 26 | oral bitherapy | 12 | 4 | DC | / | / | / | / | / | / |
| 5 | 32 | oral bitherapy | 6 | 6 | 10 | 1 | 15 | 122 (6 months) | NYHA IV | 92 | ductus arteriosus stenting and increasing doses of treprostinil |
| 6† | 0 | oral bitherapy | 0 | 0 | 13 | 1 | 13 | 164 (5 months) | DC | / | / |
| 7 | 7 | epoprostenol IV | 0 | 15 | 4 | 0 | / | / | / | / | / |
| 8 | 13 | oral bitherapy | 2 | / | / | / | 2 | 32 (8 months) | dyspnea | 1 | increasing doses of treprostinil |
| 9 | 43 | No treatment | 15 | 9 | 7 | 0 | / | / | / | / | / |
| 10 | 303 | oral bitherapy | 11 | 9 | 10 | 1 | 141 | 303 (1 month) | syncope | 11 | increasing doses of treprostinil |
(†Deceased).